新型 mRNA 疫苗在兒童癌症治療上展現潛力
New mRNA vaccine shows promise against childhood cancer
Updated at: June 21, 2026 at 01:45 AM
近期mRNA技術的進展，即廣為人知應用於COVID-19疫苗的技術，正被用來對抗兒童癌症。
Recent advancements in mRNA technology, famously used in COVID-19 vaccines, are now being harnessed to fight childhood cancer.
與用於預防的傳統疫苗不同，這些治療性疫苗旨在「重新教育」免疫系統，以辨識並清除以往曾逃避檢測的惡性腫瘤細胞。
Unlike traditional vaccines used for prevention, these therapeutic vaccines aim to 're-educate' the immune system to recognize and eliminate malignant cells that have previously evaded detection.
研究人員在神經母細胞瘤與兒童腦癌這兩大方向取得了重大突破。
Researchers are making significant progress on two major fronts: neuroblastoma and pediatric brain cancer.
針對侵襲性強的神經母細胞瘤，科學家開發了一種利用自組裝奈米顆粒的疫苗。
For neuroblastoma, a highly aggressive cancer, scientists have developed a vaccine using self-assembling nanoparticles.
此療法鎖定一種名為GPC2的蛋白質，並在臨床前試驗中成功將腫瘤體積縮小了70%。
This treatment targets a protein called GPC2 and has successfully reduced tumor volume by 70% in preclinical trials.
同時，一項開創性的臨床試驗正在澳大利亞啟動，旨在測試針對兒童腦癌的個性化mRNA疫苗。
Meanwhile, a groundbreaking clinical trial is launching in Australia to test personalized mRNA vaccines for children with brain cancer.
由於每位患者的腫瘤皆不相同，每劑疫苗均為病患量身訂製，以活化其免疫系統來對抗其特定的癌症。
Because every tumor is unique, each vaccine is custom-made for the individual patient, aiming to activate their immune system to fight their specific cancer.
這項技術提供了比傳統化療和放療更精準的替代方案，力求在提升存活率的同時，減輕常見於兒童癌症倖存者身上的嚴重副作用。
By offering a more precise alternative to conventional chemotherapy and radiation, this technology seeks to improve survival rates while minimizing the harsh side effects that often impact childhood cancer survivors.
盡管這些成果令人期待，但仍須持續進行臨床試驗，以確認這些創新療法的安全性與長期效果。
While these results are promising, ongoing clinical trials are essential to confirm the safety and long-term effectiveness of these innovative treatments.
